Ultradiluted Homeopathic Medicines Cause Apoptosis in RPMI-8226 Multiple Myeloma Cells in vitro: a Pilot Study

Abstract

Background Multiple myeloma (MM) is the second most common type of cancer among hematological malignancies and is difficult to treat. Although controversial in nature, homeopathy's effects have been tested on a wide range of cancer cell types in vitro, as well as clinically. However, homeopathic medicines have yet to be tested in MM cells. In this preliminary study, we investigated the effects of Arsenicum album, Hecla lava, Carcinosinum and Carboneum sulphuratum 200C on a human MM cell line.

Methods The RPMI-8226 MM cell line was cultured in vitro for up to 96 hours and treated with each of four homeopathic preparations. The spectrophotometric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometric Annexin V-PE/7-actinomycin D (7-AAD) and propidium iodide (PI) staining were each used to examine cell viability, apoptosis and cell cycle, respectively.

Results The MTT assay showed that all four homeopathic preparations reduced cell viability over time when compared to the control group cells, especially at 72 and 96 hours whereby only 50% of cells remained viable. Similarly, after 96 hours of treatment, the proportion of viable cells was significantly decreased and the proportion of early apoptotic (Annexin-V-PE +/7AAD-) cells was significantly increased for all four homeopathic preparations. Based on the PI-staining cell cycle data, cells treated with Hecla lava and Carboneum sulphuratum showed a statistically significant accumulation in the sub-G0/G1 phase of the cell cycle (p < 0.05).

Conclusion This is the first study to demonstrate that each of four homeopathic medicines causes apoptosis in a MM cell line. Further exploration of the potential of Arsenicum album, Hecla lava, Carcinosinum and Carboneum sulphuratum as a complementary therapeutic option in MM is warranted.

Keywords

homeopathy - cytotoxicity - apoptosis - cell cycle arrest - multiple myeloma

Publikationsverlauf

Eingereicht: 31. August 2023

Angenommen: 12. Februar 2024

Artikel online veröffentlicht:
26. Juni 2024

• References

• 1 Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev 2018; 70: 199-208
• 2 Arora S, Aggarwal A, Singla P, Jyoti S, Tandon S. Anti-proliferative effects of homeopathic medicines on human kidney, colon and breast cancer cells. Homeopathy 2013; 102: 274-282
• 3 Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol 2016; 91: 90-100
• 4 Saunders PR. Cancer treatment: is there a role for homeopathy?. Planta Med Int Open 2018; 5: S7
• 5 Sikdar S, Kumar Saha S, Rahman Khuda-Bukhsh A. Relative apoptosis-inducing potential of homeopathic Condurango 6C and 30C in H460 lung cancer cells in vitro . J Pharmacopuncture 2014; 17: 59-69
• 6 Kassab S, Cummings M, Berkovitz S, van Haselen R, Fisher P. Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev 2009; 2009: CD004845
• 7 Jonas WB, Gaddipati JP, Rajeshkumar NV. et al. Can homeopathic treatment slow prostate cancer growth?. Integr Cancer Ther 2006; 5: 343-349
• 8 Kumar KBH, Sunila ES, Kuttan G, Preethi KC, Venugopal CN, Kuttan R. Inhibition of chemically induced carcinogenesis by drugs used in homeopathic medicine. Asian Pac J Cancer Prev 2007; 8: 98-102
• 9 Es S, Kuttan G, Kc P, Kuttan R. Effect of homeopathic medicines on transplanted tumors in mice. Asian Pac J Cancer Prev 2007; 8: 390-394
• 10 MacLaughlin BW, Gutsmuths B, Pretner E. et al. Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr Cancer Ther 2006; 5: 362-372
• 11 Pathak S, Bhattacharjee N, Das JK. et al. Supportive evidence for the anticancerous potential of alternative medicine against hepatocarcinogenesis in mice. Forsch Komplement Med 2007; 14: 148-156
• 12 Pathak S, Kumar Das J, Jyoti Biswas S, Khuda-Bukhsh AR. Protective potentials of a potentized homeopathic drug, Lycopodium-30, in ameliorating azo dye induced hepatocarcinogenesis in mice. Mol Cell Biochem 2006; 285: 121-131
• 13 Milazzo S, Russell N, Ernst E. Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer 2006; 42: 282-289
• 14 Alonso-Juáreza M, Hernández-Ruíza G, Bernal FO. Cáncer de páncreas, diagnóstico y tratamiento paliativo con terapia homeopática. Rev Med Homeopat 2014; 7: 17-23
• 15 Balzarini A, Felisi E, Martini A, De Conno F. Efficacy of homeopathic treatment of skin reactions during radiotherapy for breast cancer: a randomised, double-blind clinical trial. Br Homeopath J 2000; 89: 8-12
• 16 Shang A, Huwiler-Müntener K, Nartey L. et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet 2005; 366: 726-732
• 17 Frenkel M, Mishra BM, Sen S. et al. Cytotoxic effects of ultra-diluted remedies on breast cancer cells. Int J Oncol 2010; 36: 395-403
• 18 Arora S, Tandon S. DNA fragmentation and cell cycle arrest: a hallmark of apoptosis induced by Ruta graveolens in human colon cancer cells. Homeopathy 2015; 104: 36-47
• 19 Basu N, Garg M, Tandon C, Das BC, Tandon S. Arsenicum album induces cell cycle arrest and apoptosis, and inhibits epithelial–mesenchymal transition in hormone-dependent MCF7 breast cancer cells. Homeopathy 2023; 112: 160-169
• 20 Bagot JL. How to prescribe Thuja occidentalis in oncology? Analysis of the literature, study of practices and personal experience. Rev Homeopath 2020; 11: e26-e32
• 21 Ozkan T, Hekmatshoar Y, Karabay AZ. et al. Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells. Leuk Res 2021; 102: 106523
• 22 Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745-755
• 23 Naser B, Bodinet C, Tegtmeier M, Lindequist U. Thuja occidentalis (Arbor vitae): a review of its pharmaceutical, pharmacological and clinical properties. Evid Based Complement Alternat Med 2005; 2: 69-78
• 24 Li X, Wang J, Manley JL. Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev 2005; 19: 2705-2714